0001144204-18-062657.txt : 20181130
0001144204-18-062657.hdr.sgml : 20181130
20181130170545
ACCESSION NUMBER: 0001144204-18-062657
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181130
FILED AS OF DATE: 20181130
DATE AS OF CHANGE: 20181130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schor Chen
CENTRAL INDEX KEY: 0001340875
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36641
FILM NUMBER: 181211873
MAIL ADDRESS:
STREET 1: PREDIX PHARMACEUTICALS HOLDINGS, INC.
STREET 2: 4 MAGUIRE ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC.
CENTRAL INDEX KEY: 0001137883
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 207273918
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1325 AVENUE OF AMERICAS
STREET 2: 28TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10019
BUSINESS PHONE: 201-488-0460
MAIL ADDRESS:
STREET 1: 1325 AVENUE OF AMERICAS
STREET 2: 28TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10019
FORMER COMPANY:
FORMER CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 20041122
FORMER COMPANY:
FORMER CONFORMED NAME: GOLDEN HAND RESOURCES INC
DATE OF NAME CHANGE: 20030827
FORMER COMPANY:
FORMER CONFORMED NAME: WIZBANG TECHNOLOGIES INC
DATE OF NAME CHANGE: 20010409
4
1
tv507907_4.xml
OWNERSHIP DOCUMENT
X0306
4
2018-11-30
0
0001137883
BRAINSTORM CELL THERAPEUTICS INC.
BCLI
0001340875
Schor Chen
C/O BRAINSTORM CELL THERAPEUTICS INC.
1325 AVENUE OF AMERICAS, 28TH FLOOR
NEW YORK
NY
10019
1
0
0
0
Common Stock
2018-11-30
4
A
0
2000
0
A
125558
D
Shares acquired are shares of restricted stock awarded on November 30, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.
/s/ Thomas B. Rosedale (pursuant to Power of Attorney)
2018-11-30